Insmed Inc IM8N
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if IM8N is a good fit for your portfolio.
News
Trading Information
- Previous Close Price
- $57.00
- Day Range
- $57.00–57.00
- 52-Week Range
- —–57.50
- Bid/Ask
- $59.00 / $60.50
- Market Cap
- $9.30 Bil
- Volume/Avg
- 0 / —
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 28.13
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Insmed Inc is a global biopharmaceutical company transforming the lives of patients with serious and rare diseases. The company's first commercial product is ARIKAYCE (amikacin liposome inhalation suspension), approved in the US for the treatment of Mycobacterium Avium Complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. The company's earlier-stage clinical pipeline includes Brensocatib, a novel oral reversible inhibitor of dipeptidyl peptidase 1 with therapeutic potential in non-cystic fibrosis bronchiectasis and other inflammatory diseases; and INS1009, an inhaled formulation of a treprostinil prodrug that may offer a differentiated product profile for pulmonary arterial hypertension.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Growth
- Total Number of Employees
- 912
- Website
- https://www.insmed.com
Comparables
Valuation
|
Metric
|
IM8N
|
RYTM
|
AKBA
|
|---|---|---|---|
Price/Earnings (Normalized) | — | — | — |
Price/Book Value | — | 42.34 | — |
Price/Sales | 28.13 | 27.23 | 1.10 |
Price/Cash Flow | — | — | 30.47 |
Price/Earnings
IM8N
RYTM
AKBA
Financial Strength
|
Metric
|
IM8N
|
RYTM
|
AKBA
|
|---|---|---|---|
Quick Ratio | 1.50 | 3.99 | 1.03 |
Current Ratio | 1.80 | 4.35 | 1.70 |
Interest Coverage | −8.59 | −17.19 | −5.18 |
Quick Ratio
IM8N
RYTM
AKBA
Profitability
|
Metric
|
IM8N
|
RYTM
|
AKBA
|
|---|---|---|---|
Return on Assets (Normalized) | −49.21% | −77.30% | −13.51% |
Return on Equity (Normalized) | — | −148.97% | — |
Return on Invested Capital (Normalized) | −64.60% | −146.66% | −86.71% |
Return on Assets
IM8N
RYTM
AKBA
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| Jgpygkzk | Tnhktd | $124.1 Bil | |||
| Regeneron Pharmaceuticals Inc
REGN
| Nntgwrdd | Vknznr | $114.2 Bil | |||
| Moderna Inc
MRNA
| Hxchwkqtx | Xbdl | $53.7 Bil | |||
| argenx SE ADR
ARGX
| Kpvdbnm | Mfq | $23.0 Bil | |||
| BioNTech SE ADR
BNTX
| Mgwshgncm | Bxv | $22.2 Bil | |||
| Alnylam Pharmaceuticals Inc
ALNY
| Zqqqgcx | Phjhkjr | $20.3 Bil | |||
| Biomarin Pharmaceutical Inc
BMRN
| Mswxfmgm | Trwkwh | $15.9 Bil | |||
| United Therapeutics Corp
UTHR
| Mxlzydzv | Hgg | $12.8 Bil | |||
| Incyte Corp
INCY
| Rgjrmzvg | Byqjzp | $12.2 Bil | |||
| Royalty Pharma PLC Class A
RPRX
| Xlxnxrmqb | Bfqvbc | $12.2 Bil |